As hepatitis C treatment continues to evolve, the high cost of Harvoni, a leading antiviral medication, is raising concerns among patients and healthcare providers. With a price tag often exceeding $30,000 for a typical 12-week treatment course, many individuals face significant financial barriers to accessing this life-saving drug.

Recent reports indicate that while Harvoni has proven effective in curing hepatitis C in over 95% of cases, insurance coverage and patient assistance programs are not keeping pace with rising costs. Advocacy groups are calling for policy reforms to ensure that all patients can receive necessary treatment without facing crippling financial strain.

Experts urge the pharmaceutical industry to consider more affordable pricing models, emphasizing that access to effective treatment is essential for public health. As the discussion continues, many are hopeful that changes will be made to make Harvoni and similar medications more accessible to those in need.